Home -> Law Blog Directory -> Intellectual Property Law Blogs -> The Trade Secrets Vault

Intellectual Property Law

: The Trade Secrets Vault

NovaBay Pharmaceuticals, Inc. (NBY) Receives Broadcast And Print Media Coverage

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, has recently been featured in a segment on San Francisco Bay area's KTVU-TV Channel 2 news and in an article in Genetic Engineering News. The KTVU-TV segment highlights NovaBay's lead compound in development, NVC-422, as a new way of killing bacteria without developing resistance, which is a growing problem with currently available antibiotics. The interview with Dr. Ron Najafi provides a tour of NovaBay's lab facilities as well as an overview of the mechanism of action and therapeutic product opportunities for NVC-422. This novel product candidate is currently in human clinical trials for the treatment of a variety of infectious diseases. NVC-422 is based upon small molecules that white blood cells naturally produce to destroy microbes. To continue reading this interesting article from Businesswire, click here.

Full post as published by The Trade Secrets Vault on February 23, 2009 (boomark / email).